Genetic variants in the CYP24A1 gene are associated with prostate cancer risk and aggressiveness in a Korean study population

Prostate Cancer and Prostatic Diseases

Volumn 17, Issue 2, 2014, Pages 149-156

  Oh, J J ^a   Byun, S S ^b   Lee, S E ^b   Hong, S K ^b   Jeong, C W ^b   Choi, W S ^c   Kim, D ^d   Kim, H J ^e   Myung, S C ^e  

^a CHA University   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Choi Won Suk Urology Clinic   (South Korea)

^d PENNSYLVANIA STATE UNIVERSITY   (United States)

^e Chung Ang University College of Medicine   (South Korea)

Author keywords

cancer risk; CYP24A1; polymorphism; prostate

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; COLECALCIFEROL 24 HYDROXYLASE; CYP24A1 PROTEIN, HUMAN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN;

3' UNTRANSLATED REGION; AGED; ARTICLE; CANCER LOCALIZATION; CANCER STAGING; CLINICAL EVALUATION; CONTROLLED STUDY; CYP24A1 GENE; EXON; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; POPULATION RISK; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GENE; TUMOR INVASION; ASIAN CONTINENTAL ANCESTRY GROUP; CASE CONTROL STUDY; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; PATHOLOGY; PROSTATE TUMOR; RISK; RISK FACTOR;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; KALLIKREINS; LINKAGE DISEQUILIBRIUM; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK; RISK FACTORS; VITAMIN D3 24-HYDROXYLASE;

EID: 84901188861     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2014.1     Document Type: Article

References (31)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300
2. Park SK, Sakoda LC, Kang D, Chokkalingam AP, Lee E, Shin HR et al. Rising prostate cancer rates in South Korea. Prostate 2006; 66: 1285-1291
3. Chan JM, Holick CN, Leitzmann MF, Rimm EB, Willett WC, Stampfer MJ et al. Diet after diagnosis and the risk of prostate cancer progression, recurrence, and death (United States). Cancer Causes Control 2006; 17: 199-208
4. Chen L, Davey Smith G, Evans DM, Cox A, Lawlor DA, Donovan J et al. Genetic variants in the vitamin D receptor are associated with advanced prostate cancer at diagnosis: Findings from the prostate testing for cancer and treatment study and a systematic review. Cancer Epidemiol Biomarkers Prev 2009; 18: 2874-2881
5. Schumacher FR, Berndt SI, Siddiq A, Jacobs KB, Wang Z, Lindstrom S et al. Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet 2011; 20: 3867-3875
6. Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet 2013; 45: 385-391
7. Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Hollis BW, Giovannucci E. Plasma 1, 25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 2004; 15: 255-265
8. Li H, Stampfer MJ, Hollis JB, Mucci LA, Gaziano JM, Hunter D et al. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med 2007; 4: E103
9. Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Hollis BW, Giovannucci E. Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25- hydroxyvitamin D and 1, 25-dihydroxyvitamin D, and prostate cancer risk. Prostate 2007; 67: 911-923
10. Ahonen MH, Zhuang YH, Aine R, Ylikomi T, Tuohimaa P. Androgen receptor and vitamin D receptor in human ovarian cancer: Growth stimulation and inhibition by ligands. Int J Cancer 2000; 86: 40-46
11. Ahn J, Albanes D, Berndt SI, Peters U, Chatterjee N, Freedman ND et al. Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. Carcinogenesis 2009; 30: 769-776
12. Beuten J, Gelfond JA, Franke JL, Weldon KS, Crandall AC, Johnson-Pais TL et al. Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2009; 18: 1869-1880
13. Holick CN, Stanford JL, Kwon EM, Ostrander EA, Nejentsev S, Peters U. Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer. Cancer Epidemiol Biomarkers Prev 2007; 16: 1990-1999
14. Harris SS, Dawson-Hughes B. Seasonal changes in plasma 25-hydroxyvitamin D concentrations of young American black and white women. Am J Clin Nutr 1998; 67: 1232-1236
15. Harris SS, Soteriades E, Coolidge JA, Mudgal S, Dawson-Hughes B. Vitamin D insufficiency and hyperparathyroidism in a low income, multiracial, elderly population. J Clin Endocrinol Metab 2000; 85: 4125-4130
16. Zadshir A, Tareen N, Pan D, Norris K, Martins D. The prevalence of hypovitaminosis D among US adults: Data from the NHANES III. Ethn Dis 2005; 15: S5-97-101
17. Song SY, Kim SR, Ahn G, Choi HY. Pathologic characteristics of prostatic adenocarcinomas: A mapping analysis of Korean patients. Prostate Cancer Prostatic Dis 2003; 6: 143-147
18. Oliphant A, Barker DL, Stuelpnagel JR, Chee MS. BeadArray technology: Enabling an accurate, cost-effective approach to high-Throughput genotyping. Biotechniques 2002; Suppl: 56-8: 60-61
19. Morris JA, Gardner MJ. Calculating confidence intervals for relative risks (odds ratios) and standardised ratios and rates. Br Med J (Clin Res Ed) 1988; 296: 1313-1316
20. Lewis CM. Genetic association studies: Design, analysis and interpretation. Brief Bioinform. 2002; 3: 146-153
21. Hedrick PW. Gametic disequilibrium measures: Proceed with caution. Genetics 1987; 117: 331-341
22. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68: 978-989
23. Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 2004; 74: 765-769
24. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001; 125: 279-284
25. Leman ES, DeMiguel F, Gao AC, Getzenberg RH. Regulation of androgen and vitamin D receptors by 1, 25-dihydroxyvitamin D3 in human prostate epithelial and stromal cells. J Urol 2003; 170: 235-240
26. Omdahl JL, Morris HA, May BK. Hydroxylase enzymes of the vitamin D pathway: Expression, function, and regulation. Annu Rev Nutr. 2002; 22: 139-166
27. Nomura AM, Stemmermann GN, Lee J, Kolonel LN, Chen TC, Turner A et al. Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control 1998; 9: 425-432
28. Mondul AM, Shui IM, Yu K, Travis RC, Stevens VL, Campa D et al. Genetic variation in the vitamin D pathway in relation to risk of prostate cancer-results from the breast and prostate cancer cohort consortium. Cancer Epidemiol Biomarkers Prev 2013; 22: 688-696
29. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 1990; 10: 1307-1311
30. Nejentsev S, Godfrey L, Snook H, Rance H, Nutland S, Walker NM et al. Comparative high-resolution analysis of linkage disequilibrium and tag single nucleotide polymorphisms between populations in the vitamin D receptor gene. Hum Mol Genet 2004; 13: 1633-1639
31. Feskanich D, Hunter DJ, Willett WC, Hankinson SE, Hollis BW, Hough HL et al. Vitamin D receptor genotype and the risk of bone fractures in women. Epidemiology 1998; 9: 535-539